Skip to main content

Advertisement

Table 4 Reported adverse events (side effects)

From: Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

  Site 1 Site 2
AL (N = 175) AQAS (N = 172) p-value* AL (N = 165) AQAS (N = 168) p-value*
Any adverse event
 Caregiver reported 6 (3.4%) 27 (15.7%) < 0.001 25 (15.2%) 41 (24.4%) 0.039
Specific adverse events
 Vomiting 4 (2.3%) 16 (9.3%) 0.005 13 (7.9%) 18 (10.7%) 0.452
 Weakness-Fatigue 0 (0.0%) 12 (7.0%) < 0.001 9 (5.5%) 29 (17.3%) 0.001
 Dizziness 0 (0.0%) 10 (5.8%) 0.001 7 (4.2%) 4 (2.4%) 0.376
 Diarrhoea 1 (0.6%) 3 (1.7%) 0.369 2 (1.2%) 2 (1.2%) 1.000
 Other gastrointestinal complaintsa 1 (0.6%) 5 (2.9%) 0.119 2 (1.2%) 4 (2.4%) 0.685
 Other AE reportedb 1 (0.6%) 2 (1.2%) 0.621 4 (2.4%) 4 (2.4%) 1.000
  1. * Fisher’s exact test
  2. aReported one or more of the following: diarrhoea, anorexia, nausea or abdominal pain
  3. b Other AE’s reported: Site 1— AL: 1 pruritic; AQAS: 1 headache & 1 not specified. Site 2—AL: 2 change in urine colour, 1 cold/flu, & 1 sweating; AQAS: 1 change in urine colour, 1 fever, 1 mouth sores & 1 unspecified